Zdenek Hel

Zdenek Hel

Auto-generated profile, based on publicly available information

Zdenek Hel

Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2014 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
NBNathan L. Bowers
Nathan L. Bowers
EHE. Scott Helton
E. Scott Helton
RHRichard P. H. Huijbregts
Richard P. H. Huijbregts
PGPaul A. Goepfert
Paul A. Goepfert
SHSonya L. Heath
Sonya L. Heath
ZHZdenek Hel
Zdenek Hel
HIV-1 infection is associated with a progressive loss of T cell functional capacity and reduced responsiveness to antigenic stimuli. The mechanisms underlying T cell dysfunction in HIV-1/AIDS are not completely understood. Multiple studies have shown that binding of program death ligand 1 (PD-L1) on the surface of monocytes and dendritic cells to PD-1 on T cells negatively regulates T cell function. Here we show that neutrophils in the blood of HIV-1-infected individuals express high levels of PD-L1. PD-L1 is induced by HIV-1 virions, TLR-7/8 ligand, bacterial lipopolysaccharide (LPS), and IFNα. Neutrophil PD-L1 levels correlate with the expression of PD-1 and CD57 on CD4+ and CD8+ T cells, elevated levels of neutrophil degranulation markers in plasma, and increased frequency of low density neutrophils (LDNs) expressing the phenotype of granulocytic myeloid-derived suppressor cells (G-MDSCs). Neutrophils purified from the blood of HIV-1-infected patients suppress T cell function via several mechanisms including PD-L1/PD-1 interaction and production of reactive oxygen species (ROS). Collectively, the accumulated data suggest that chronic HIV-1 infection results in an induction of immunosuppressive activity of neutrophils characterized by high expression of PD-L1 and an inhibitory effect on T cell function. Despite 30 years of intensive research, our understanding of how HIV-1 virus undermines the ability of the immune system to fight common infections is limited. Although we know that T cells, a key cell population that normally fights invading pathogens, lose their ability to function in HIV-1-infected individuals, we do not fully understand why. Here, we found that HIV-1 virus activates another type of cells, neutrophils, the most common type of white cell in the blood. Activated neutrophils negatively affect the function of T cells and prevent them from producing cytokines, protective proteins that serve as messengers orchestrating the immune response to bacteria and viruses. This newly identified mechanism of immune suppression mediated by neutrophils may alter our understanding of HIV-1 pathogenesis and result in a design of novel therapies targeting the loss of immune function in HIV-1/AIDS.

1 December 2001 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
IBIgor M. Belyakov
Igor M. Belyakov
ZHZdenek Hel
Zdenek Hel
BKBrian Kelsall
Brian Kelsall
VKVladimir A. Kuznetsov
Vladimir A. Kuznetsov
JAJeffrey D. Ahlers
Jeffrey D. Ahlers
JBJay A. Berzofsky
Jay A. Berzofsky

1 January 2002 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
RPR. Pal
R. Pal
DVD. Venzon
D. Venzon
NLN. L. Letvin
N. L. Letvin
SSS. Santra
S. Santra
DMD. C. Montefiori
D. C. Montefiori
GFGenoveffa Franchini
Genoveffa Franchini
T-cell-mediated immune effector mechanisms play an important role in the containment of human immunodeficiency virus/simian immunodeficiency virus (HIV/SIV) replication after infection. Both vaccination- and infection-induced T-cell responses are dependent on the host major histocompatibility complex classes I and II (MHC-I and MHC-II) antigens. Here we report that both inherent, host-dependent immune responses to SIVmac251infection and vaccination-induced immune responses to viral antigens were able to reduce virus replication and/or CD4+T-cell loss. Both the presence of the MHC-I Mamu-A*01 genotype and vaccination of rhesus macaques with ALVAC-SIV-gag-pol-env(ALVAC-SIV-gpe) contributed to the restriction of SIVmac251replication during primary infection, preservation of CD4+T cells, and delayed disease progression following intrarectal challenge exposure of the animals to SIVmac251 (561). ALVAC-SIV-gpeimmunization induced cytotoxic T-lymphocyte (CTL) responses cumulatively in 67% of the immunized animals. Following viral challenge, a significant secondary virus-specific CD8+T-cell response was observed in the vaccinated macaques. In the same immunized macaques, a decrease in virus load during primary infection (P= 0.0078) and protection from CD4 loss during both acute and chronic phases of infection (P= 0.0099 andP= 0.03, respectively) were observed. A trend for enhanced survival of the vaccinated macaques was also observed. Neither boosting the ALVAC-SIV-gpewith gp120 immunizations nor administering the vaccine by the combination of mucosal and systemic immunization routes increased significantly the protective effect of the ALVAC-SIV-gpevaccine. While assessing the role of MHC-I Mamu-A*01 alone in the restriction of viremia following challenge of nonvaccinated animals with other SIV isolates, we observed that the virus load was not significantly lower in Mamu-A*01-positive macaques following intravenous challenge with either SIVmac251 (561)or SIVSME660. However, a significant delay in CD4+T-cell loss was observed in Mamu-A*01-positive macaques in each group. Of interest, in the case of intravenous or intrarectal challenge with the chimeric SIV/HIV strains SHIV89.6Por SHIVKU2, respectively, MHC-I Mamu-A*01-positive macaques did not significantly restrict primary viremia. The finding of the protective effect of the Mamu-A*01 molecule parallels the protective effect of the B*5701 HLA allele in HIV-1-infected humans and needs to be accounted for in the evaluation of vaccine efficacy against SIV challenge models.

10 November 2009 in Endocrine Reviews
Verified
Journal Article
Open access
PDF file
ZHZdenek Hel
Zdenek Hel
ESElizabeth Stringer
Elizabeth Stringer
JMJiri Mestecky
Jiri Mestecky
Worldwide, an increasing number of women use oral or injectable hormonal contraceptives. However, inadequate information is available to aid women and health care professionals in weighing the potential risks of hormonal contraceptive use in individuals living with HIV-1 or at high risk of infection. Numerous epidemiological studies and challenge studies in a rhesus macaque model suggest that progesterone-based contraceptives increase the risk of HIV-1 infection in humans and simian immunodeficiency virus (SIV) infection in macaques, accelerate disease progression, and increase viral shedding in the genital tract. However, because several other studies in humans have not observed any effect of exogenously administered progesterone on HIV-1 acquisition and disease progression, the issue continues to be a topic of intense research and ongoing discussion. In contrast to progesterone, systemic or intravaginal treatment with estrogen efficiently protects female rhesus macaques against the transmission of SIV, likely by enhancing the natural protective properties of the lower genital tract mucosal tissue. Although the molecular and cellular mechanisms underlying the effect of sex steroid hormones on HIV-1 and SIV acquisition and disease progression are not well understood, progesterone and estrogen are known to regulate a number of immune mechanisms that may exert an effect on retroviral infection. This review summarizes current knowledge of the effects of various types of sex steroid hormones on immune processes involved in the biology of HIV-1 infection.

1 October 2000 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ZHZdenek Hel
Zdenek Hel
DVDavid Venzon
David Venzon
MPMonita Poudyal
Monita Poudyal
WTWen-Po Tsai
Wen-Po Tsai
LGLaura Giuliani
Laura Giuliani
GFGenoveffa Franchini
Genoveffa Franchini

1 November 2002 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
ZHZdenek Hel
Zdenek Hel
JNJanos Nacsa
Janos Nacsa
ETElżbieta Anna Tryniszewska
Elżbieta Anna Tryniszewska
WTWen-Po Tsai
Wen-Po Tsai
RPRobyn Washington Parks
Robyn Washington Parks
GFGenoveffa Franchini
Genoveffa Franchini
Macaques infected with the SIV strain SIVmac251 develop a disease closely resembling human AIDS characterized by high viremia, progressive loss of CD4+ T cells, occurrence of opportunistic infection, cachexia, and lymphomas. We report in this study that vaccination with the genetically attenuated poxvirus vector expressing the structural Ags of SIVmac (NYVAC-SIV-gag, pol, env) in combination with priming with DNA-SIV-gag, env resulted in significant suppression of viremia within 2 mo after mucosal exposure to the highly pathogenic SIVmac251 in the majority of vaccinated macaques. The control of viremia in these macaques was long lasting and inversely correlated to the level of both pre- and postchallenge Gag-specific lymphoproliferative responses, as well as to the level of total SIV-specific CD4+ T lymphocyte responses at the peak of acute viremia as detected by intracellular cytokine-staining assay. Viremia containment also correlated with the frequency of the immunodominant Gag181–189CM9 epitope-specific CD8+ T cells present before the challenge or expanded during acute infection. These data indicate, for the first time, the importance of vaccine-induced CD4+ Th cell responses as an immune correlate of viremia containment. The results presented in this work also further demonstrate the potential of a DNA-prime/attenuated poxvirus-boost vaccine regimen in an animal model that well mirrors human AIDS.